The Controlled Human Infection Model for Enterotoxigenic Escherichia coli.

3区 医学 Q2 Medicine Current topics in microbiology and immunology Pub Date : 2024-01-01 DOI:10.1007/82_2021_242
Chad K Porter, Kawsar R Talaat, Sandra D Isidean, Alwine Kardinaal, Subhra Chakraborty, Ramiro L Gutiérrez, David A Sack, A Louis Bourgeois
{"title":"The Controlled Human Infection Model for Enterotoxigenic Escherichia coli.","authors":"Chad K Porter, Kawsar R Talaat, Sandra D Isidean, Alwine Kardinaal, Subhra Chakraborty, Ramiro L Gutiérrez, David A Sack, A Louis Bourgeois","doi":"10.1007/82_2021_242","DOIUrl":null,"url":null,"abstract":"<p><p>The controlled human infection model (CHIM) for enterotoxigenic Escherichia coli (ETEC) has been instrumental in defining ETEC as a causative agent of acute watery diarrhea, providing insights into disease pathogenesis and resistance to illness, and enabling preliminary efficacy evaluations for numerous products including vaccines, immunoprophylactics, and drugs. Over a dozen strains have been evaluated to date, with a spectrum of clinical signs and symptoms that appear to replicate the clinical illness seen with naturally occurring ETEC. Recent advancements in the ETEC CHIM have enhanced the characterization of clinical, immunological, and microbiological outcomes. It is anticipated that omics-based technologies applied to ETEC CHIMs will continue to broaden our understanding of host-pathogen interactions and facilitate the development of primary and secondary prevention strategies.</p>","PeriodicalId":11102,"journal":{"name":"Current topics in microbiology and immunology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current topics in microbiology and immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/82_2021_242","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

The controlled human infection model (CHIM) for enterotoxigenic Escherichia coli (ETEC) has been instrumental in defining ETEC as a causative agent of acute watery diarrhea, providing insights into disease pathogenesis and resistance to illness, and enabling preliminary efficacy evaluations for numerous products including vaccines, immunoprophylactics, and drugs. Over a dozen strains have been evaluated to date, with a spectrum of clinical signs and symptoms that appear to replicate the clinical illness seen with naturally occurring ETEC. Recent advancements in the ETEC CHIM have enhanced the characterization of clinical, immunological, and microbiological outcomes. It is anticipated that omics-based technologies applied to ETEC CHIMs will continue to broaden our understanding of host-pathogen interactions and facilitate the development of primary and secondary prevention strategies.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肠毒性大肠杆菌的控制性人体感染模型。
肠毒性大肠杆菌 (ETEC) 的人类感染控制模型 (CHIM) 在确定 ETEC 为急性水样腹泻的致病菌、深入了解疾病的发病机制和抗病能力以及对疫苗、免疫乳剂和药物等多种产品进行初步疗效评估方面发挥了重要作用。迄今为止,已对十多种菌株进行了评估,其临床症状和体征似乎与自然发生的 ETEC 临床疾病相同。ETEC CHIM 的最新进展加强了对临床、免疫学和微生物学结果的描述。预计基于 omics 的技术应用于 ETEC CHIMs 将继续拓宽我们对宿主-病原体相互作用的理解,并促进一级和二级预防策略的开发。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.60
自引率
0.00%
发文量
26
审稿时长
>12 weeks
期刊介绍: The review series Current Topics in Microbiology and Immunology provides a synthesis of the latest research findings in the areas of molecular immunology, bacteriology and virology. Each timely volume contains a wealth of information on the featured subject. This review series is designed to provide access to up-to-date, often previously unpublished information.
期刊最新文献
A Brief History of Polyclonal Antibody Therapies Against Bacterial and Viral Diseases Before COVID-19. Alterations of the AKT Pathway in Sporadic Human Tumors, Inherited Susceptibility to Cancer, and Overgrowth Syndromes. Evidence for the Efficacy of COVID-19 Convalescent Plasma. HemoClear: A Practical and Cost-Effective Alternative to Conventional Convalescent Plasma Retrieval Methods. Monoclonal Antibody Therapies Against SARS-CoV-2: Promises and Realities.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1